Science has come a long way in containing infectious diseases over the past five decades. Despite this progress, the incidence of dengue fever has increased thirty-fold, with 390 million people infected annually worldwide.
Now, with several dengue virus vaccine candidates at various stages of clinical development, SFI Omidyar Fellow Ben Althouse and his collaborators are examining how the virus circulates in the wild — beyond the reach of vaccines — and the relationships among the virus, the mosquitoes that carry it, and the primate hosts (including humans) it infects.
In much of the developing world, climate change and the urban slum phenomenon continue to increase the risk of infection by dengue and other mosquito-borne pathogens. A successful dengue vaccine would reduce the incidence of the painful and sometimes fatal disease in humans. But wild primates can’t be vaccinated, so the virus will continue to infect both wild and human primate hosts as the same mosquitoes feed on both populations.
Althouse explains that it is crucial to understand dengue in wild populations, “so we can effectively mitigate the morbidity and mortality that result from a virus whose transmission we have little control over.”
Their paper, published this week in the journal Virology, examines results from some 54 different dengue virus-related studies of non-human primates and provides estimates of how long after inoculation there is detectable virus in the blood and how different viral strains behave.
“The longer there’s virus in a primate’s blood, the greater the chance a mosquito will ingest the virus and then transmit to another host — human or monkey,” Althouse explains.
Their analysis finds that the differences among the 11 species of apes and old world and new world monkeys tested are minimal.
Althouse says the new estimates might improve prediction of dengue epidemics in wild populations — which in turn might help protect endangered primates and lessen the degree of spillover to people living near their wild primate kin.
Co-authors include Derek Cummings and Anna Durbin of the Johns Hopkins Bloomberg School of Public Health, Kathryn Hanley of New Mexico State University, Scott Weaver of the University of Texas Medical Branch, Galveston, and Scott Halstead.
Read the paper in Virology (March 2014)